Dendritic cells (DC) are the most potent antigen presenting cells (APC) for initiating cellular immune responses through the stimulation of naive T cells. DC have now moved to the main stage of active cancer immunotherapy. Leukemic cells evade host immune surveillance by lacking expression of co-stimulatory molecules or adhesion molecules. Thus, it may be possible to treat patients with leukemia by manipulation of the immune system using APC with increased potency, such as DC. This mini-review will focus mainly on immunological approaches using monocyte-derived DC with leukemic antigens and leukemic cell-derived DC to the therapy of acute myelogenous leukemia.